These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32798298)

  • 1. Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer (FINEX pilot study).
    Keino D; Yokosuka T; Hirose A; Sakurai Y; Nakamura W; Fujita S; Hayashi A; Miyagawa N; Iwasaki F; Hamanoue S; Yanagimachi M; Shiomi M; Goto S; Kitagawa N; Tanaka M; Nozawa K; Tanaka Y; Goto H
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28655. PubMed ID: 32798298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
    Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
    Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
    Mody R; Zhao L; Yanik GA; Opipari V
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
    Federico SM; Caldwell KJ; McCarville MB; Daryani VM; Stewart CF; Mao S; Wu J; Davidoff AM; Santana VM; Furman WL; Pappo AS; Navid F
    Eur J Cancer; 2020 Jun; 132():35-42. PubMed ID: 32325418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
    El-Khoueiry AB; O'Donnell R; Semrad TJ; Mack P; Blanchard S; Bahary N; Jiang Y; Yen Y; Wright J; Chen H; Lenz HJ; Gandara DR
    Cancer Chemother Pharmacol; 2018 May; 81(5):957-963. PubMed ID: 29520435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
    Suenaga M; Wakatsuki T; Mashima T; Ogura M; Ichimura T; Shinozaki E; Nakayama I; Osumi H; Ota Y; Takahari D; Chin K; Seimiya H; Yamaguchi K
    Invest New Drugs; 2020 Feb; 38(1):111-119. PubMed ID: 30838483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
    Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
    Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
    Meany HJ; Widemann BC; Hinds PS; Bagatell R; Shusterman S; Stern E; Jayaprakash N; Peer CJ; Figg WD; Hall OM; Sissung TM; Kim A; Fox E; London WB; Rodriguez-Galindo C; Minturn JE; Dome JS
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29282. PubMed ID: 34383370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
    Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.
    Miyamoto M; Takano M; Kuwahara M; Soyama H; Kato K; Matuura H; Sakamoto T; Takasaki K; Aoyama T; Yoshikawa T; Furuya K
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):111-117. PubMed ID: 29124328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
    Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
    Ooka Y; Chiba T; Ogasawara S; Arai K; Suzuki E; Tawada A; Yamashita T; Kanai F; Kaneko S; Yokosuka O
    Invest New Drugs; 2014 Aug; 32(4):723-8. PubMed ID: 24599799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
    Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
    Kawahara M; Kubo A; Komuta K; Fujita Y; Sasaki Y; Fukushima M; Daimon T; Furuse K; Mishima M; Mio T
    J Thorac Oncol; 2012 Dec; 7(12):1845-1849. PubMed ID: 22139390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
    DuBois SG; Granger MM; Groshen S; Tsao-Wei D; Ji L; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H; Villablanca JG; Vo KT; Pinto N; Mosse YP; Maris JM; Shusterman S; Cohn SL; Goldsmith KC; Weiss B; Yanik GA; Twist CJ; Irwin MS; Haas-Kogan DA; Park JR; Marachelian A; Matthay KK
    J Clin Oncol; 2021 Nov; 39(31):3506-3514. PubMed ID: 34270348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218.
    Deyell RJ; Wu B; Rassekh SR; Tu D; Samson Y; Fleming A; Bouffet E; Sun X; Powers J; Seymour L; Baruchel S; Morgenstern DA
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27540. PubMed ID: 30393943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
    Zsíros J; Brugières L; Brock P; Roebuck D; Maibach R; Child M; Morland B; Casanova M; Pariente D; Paris C; de Camargo B; Ronghe M; Zimmermann A; Plaschkes J; Czauderna P; Perilongo G
    Eur J Cancer; 2012 Dec; 48(18):3456-64. PubMed ID: 22835780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.